Get the Stockscreener App
140.64
2.60%
3.56
Biogen Inc stock is traded at $140.64, with a volume of 1.77M.
It is up +2.60% in the last 24 hours and down -0.24% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$137.08
Open:
$138
24h Volume:
1.77M
Relative Volume:
1.21
Market Cap:
$20.59B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
12.70
EPS:
11.07
Net Cash Flow:
$1.77B
1W Performance:
+2.41%
1M Performance:
-0.24%
6M Performance:
-31.79%
1Y Performance:
-36.39%
1-Day Range:
$137.56
$141.50
1-Week Range:
$135.02
$141.50
52-Week Range:
$128.51
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
140.64 | 20.59B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Allianz Asset Management GmbH Has $81.96 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen Inc. (NASDAQ:BIIB) Stock Position Increased by Meitav Investment House Ltd. - MarketBeat
Ieq Capital LLC Buys 55,514 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Stock Is Mutating Into a Value Play - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
What is Wedbush's Forecast for Biogen Q1 Earnings? - MarketBeat
Alberta Investment Management Corp Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $751,000 Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
New York State Teachers Retirement System Sells 6,673 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome - Contract Pharma
Biogen's (BIIB) "Neutral" Rating Reiterated at Piper Sandler - MarketBeat
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative - Simply Wall St
Kentucky Retirement Systems Insurance Trust Fund Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Oppenheimer maintains Biogen Outperform with $255 target - Investing.com
Biogen stock price target cut to $159 by Bernstein SocGen - Investing.com Australia
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Piper Sandler cuts Biogen price target to $135, keeps neutral rating - Investing.com India
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Biogen | Investor Relations
Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan
Biogen's SWOT analysis: stock faces challenges amid pipeline potential - Investing.com
Rhumbline Advisers Has $41.07 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Banque Pictet & Cie SA Raises Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cantor Fitzgerald Reduces Earnings Estimates for Biogen - MarketBeat
Biogen's (BIIB) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
Morgan Stanley Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
The Goldman Sachs Group Cuts Biogen (NASDAQ:BIIB) Price Target to $245.00 - MarketBeat
Stephens Inc. AR Sells 2,270 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat
19,574 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Strategic Financial Concepts LLC - MarketBeat
Viral Gene Therapy Market May See a Big Move | Biogen, Novartis AG, Gilead Sciences - openPR
Vontobel Holding Ltd. Increases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges - BSA bureau
William Blair Issues Optimistic Estimate for Biogen Earnings - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):